Clinical trial
Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma:AVESEC Trial - AVESEC Study
NCT07460245 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma:AVESEC Trial - AVESEC Study
- Lead sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- June 30, 2026
- Completion date
- December 31, 2030
- Enrollment
- 144 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
urothelial carcinoma